Exelixis
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
EXEL News
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expecta...
As you might know, Exelixis, Inc. (NASDAQ:EXEL) last week released its latest quarterly, and things did not turn out so great for shareholders. Results showed a...
Loading... Loading... Exelixis EXEL underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The tabl...
Analyst ratings
68%
of 22 ratingsMore EXEL News
Exelixis, Inc. EXEL reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement. EXEL reco...
Participants Amy C. Peterson; Executive VP, Product Development & Medical Affairs and Chief Medical Officer; Exelixis, Inc. Christopher J. Senner; Executive V...
TD Cowen analyst Yaron Werber raised the firm’s price target on Exelixis to $27 from $25 and keeps a Buy rating on the shares. The firm said investor focus rema...
For the quarter ended March 2024, Exelixis (EXEL) reported revenue of $425.23 million, up 4% over the same period last year. EPS came in at $0.17, compared to $...
Total Revenue: Reported at $425.2 million for Q1 2024, showing an increase from $408.8 million in Q1 2023, but fell short of the estimated $460.62 million. Net...
Reports Q1 revenue $425.2M, consensus $460.62M. “In the first quarter of 2024, Exelixis made important progress to advance a diverse, multi-product portfolio of...
- Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GA...
